clinical trial · NCT04614467
A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction
Coronary Microvascular DysfunctionCoronary Microvascular DiseaseMicrovascular Coronary Artery DiseaseCLBS16Placebo
brief summary
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
started
Oct 29, 2020
primary completion
Sep 28, 2022
completion
Sep 28, 2022
last updated
May 4, 2026
official title
A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol